Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

45.80 -0.35 (-0.77%)
Streaming Delayed Price Updated: 11:04 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
79 80 Next >
Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast
Bristol Myers Squibb reported Q2 revenues of $12.2 billion, surpassing the consensus of $11.55B, driven by its Growth Portfolio and Eliquis. The company's adjusted EPS of $2.07 beat expectations of... 
Via Benzinga
Topics Earnings
US Stocks Look To End Week On High Note As Nvidia Leads Mega-Caps Higher In Premarket Ahead Of Key Inflation Data
After the severe pounding the tech space received in the past three sessions, it might be rebound time. However, any recovery will largely hinge on whether key inflation data confirms the continued... 
Via Benzinga
Topics Economy
Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps
The drug giant also raised guidance. 
Via Investor's Business Daily
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
A Glimpse Into The Expert Outlook On Bristol-Myers Squibb Through 4 Analysts
 
Via Benzinga
What the Options Market Tells Us About Bristol-Myers Squibb
 
Via Benzinga
S&P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In 'Fear' Zone
 
Via Benzinga
Topics Stocks
Bristol-Myers Squibb, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday
 
Via Benzinga
DECK, SKX Higher After Earnings; PCE On Tap Friday
It’s tough to get a firm handle on this market. One day it looks like a trading rotation into undervalued equities from big run-ups elsewhere, the next day it’s a major selloff across the board. 
Via Talk Markets
2 High-Yield Dividend Stocks Billionaires Are Buying. Are They Right for You?
Billionaires are buying these stocks, but that doesn't necessarily make them right for your portfolio. 
Via The Motley Fool
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
High Dividend 50: Bristol-Myers Squibb
This article will examine the prospects of Bristol-Myers as an investment opportunity. 
Via Talk Markets
Bristol-Myers Squibb Unusual Options Activity For July 15
 
Via Benzinga
Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. 
Via Benzinga
3 Defensive Stocks to Shield Your Portfolio in July
Fed Chair Jerome Powell’s cautious economic outlook adds to the allure of defensive stocks offering stable long-term returns 
Via InvestorPlace
Topics Economy
7 Value Stocks to Buy at a 52-Week Low in July
Bottom fishers and contrarians take note: each of these seven value stocks to buy is on sale after recently hitting new 52-week lows. 
Via InvestorPlace
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
Via Benzinga
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Collect $2,000 in Dividends Per Year by Investing $35,000 in These 3 Stocks
These stocks all pay more than four times the S&P 500 average. 
Via The Motley Fool
Topics Stocks
US Bancorp Posts Upbeat Earnings, Joins Aehr Test Systems, Hancock Whitney And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
 
Via Benzinga
Topics Bankruptcy
Got $500? 2 No-Brainer Growth Stocks to Buy and Hold Forever
These businesses are begging to be bought. 
Via The Motley Fool
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. 
Via Talk Markets
Topics Initial Public Offering
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
These stocks all yield more than 3%. 
Via The Motley Fool
2 Pharma Stocks to Buy Hand Over Fist This Month
These drugmakers may not be in perfect health right now, but that shouldn't last much longer. 
Via The Motley Fool
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Undervalued Stocks Ready for a Breakout This Summer
Undervalued breakout stocks are heating up this summer. Discover three hidden gems with strong fundamentals ready to outperform the market. 
Via InvestorPlace
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
79 80 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.